Is Scinai Immunotherapeutics Ltd. (SCNI) a Buy, Sell, or Hold?
NASDAQ : SCNI
Scinai Immunotherapeutics Ltd. — News
$0.258 USD
$0.01 (5.18%)
- Volume
- 62.11K
- Average Volume
- 417.92K
- Market Capitalization
- $339.36K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.97
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.35
| Source | Headline |
|---|---|
|
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. prnewswire.com - 2026-08-10 06:34:00 |
|
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating CDMO subsidiary, today reported financial results for the three months ended March 31, 2026 and provided a corporate update. prnewswire.com - 2026-06-10 07:55:00 |
|
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, today announced that its wholly owned subsidiary, Scinai Biopharma Services Ltd. prnewswire.com - 2026-05-20 07:00:00 |
|
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands. prnewswire.com - 2026-05-15 08:05:00 |
